



# EXOME SEQUENCING

Experience the power of clinical genetic testing


## EXOME SEQUENCING A POWERFUL DIAGNOSTIC TOOL A BREAKTHROUGH SOLUTION TO SOLVE MEDICAL DILEMMAS

Exome Sequencing by CGC Genetics combines the highest diagnostic yield available with the clinical interpretation and integration provided by our specialized Medical Team. With Exome Sequencing, patients can be studied with a significantly reduced turnaround time and cost, when compared with previous sequential approach of single gene or gene panel sequencing.


CGC Genetics has available two Exome Sequencing options, to best fit patient's individual needs:

- Whole Exome Sequencing, which analyzes the entire exome by sequencing about 20 000 genes;
- Disease Exome by CGC Genetics, which analyzes >6 000 clinically relevant genes.

Related to disease or clinical phenotype



The entire human exome comprises over 20 000 genes



### Clinical Indications for Exome Sequencing:

- Undiagnosed genetic condition not identified with prior genetic testing
- Clinical phenotype that may overlap with several genetic disorders
- Clinical phenotype that does not correspond to any known genetic disorder
- Clinical phenotype which is unclear or complex and/or may involve multiple genes
- A genetic disorder for which no genetic testing is available, is suspected

**Whole Exome Sequencing**

- Full genome search
- Searching for a new gene association

**Disease Exome by CGC Genetics**

- Focused on clinically relevant genes

## WHOLE EXOME SEQUENCING – WES

Whole Exome Sequencing (WES) entails the sequencing of all genomic coding regions, i.e., the exons.

The goal is to obtain the highest possible amount of genetic information of a patient by searching genetic variants throughout the 20 000 genes that make up the exome.

Since this test yields many thousands of genetic variants to be analyzed CGC Genetics recommends WES TRIO, i.e., performing WES in both the patient and the parents. This way, it is possible that both parents serve as a reference for filtering benign variants, or ascertain the parent-of-origin for each variant, making WES an effective diagnostic method in detecting, e.g., recessive Mendelian diseases and de novo variants.

Variants may be either detected in genes related with defined clinical conditions or in genes whose association with disease has not been yet described.

Whole Exome Sequencing has an average depth of coverage of 100x. This entails a very thorough study of coding sequences analyzed with high diagnostic yield in most regions

### WES ADVANTAGES:

- Maximum diagnostic yield currently available
- Clinical phenotype expansion through the identification of new genes with clinical significance
  - Detection of new variants or gene associations not yet described
    - Confirmation of possible variants by Sanger sequencing
      - Solving complex diagnostic cases
  - Report with clinical integration and interpretation

## DISEASE EXOME by CGC Genetics

Disease Exome by CGC Genetics is the largest sequencing panel available which includes approximately >6 000 clinically relevant genes.

Disease Exome has a particular focus on coding regions (exons) and in flanking regions (splicing sites) and is based on the following databases:

1. Human Gene Mutation Database (HGMD) ([www.hgmd.cf.ac.uk/ac/index.php](http://www.hgmd.cf.ac.uk/ac/index.php))
2. Online Mendelian Inheritance in Man (OMIM) ([www.omim.org](http://www.omim.org))
3. GeneTests ([www.genetests.org](http://www.genetests.org))

Disease Exome by CGC Genetics is designed to produce an average depth of coverage of 100x and minimum 20x in more than 95% of target regions.

### DISEASE EXOME ADVANTAGES:

- Targeted at clinically relevant genes;
  - High diagnostic yield
- Confirmation of possible variants by Sanger sequencing
  - Report with clinical integration and interpretation
- Useful in situations where only the patient sample is available

## MITOCHONDRIAL DNA TEST

In exome sequencing only nuclear DNA is analyzed, excluding mitochondrial DNA. Mitochondrial genome contains 37 genes involved in several mitochondrial disorders.

CGC Genetics offers a panel for detection of mitochondrial diseases, which includes full sequencing analysis by NGS of the whole mitochondrial genome.

## METHODOLOGY


### Next Generation Sequencing – NGS

Next Generation Sequencing (NGS) is the most advanced technology for sequencing analysis. In a single test, a gene, several genes (panel) or the whole exome are analyzed at a fraction of the time and cost than before.

This technology provided a breakthrough in genetic diagnostic yield, reducing turnaround time and cost.



## METHODOLOGY PROCESS



<sup>1</sup> Richards S et al., Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in Medicine*. 2015, 17(5):405-24. DOI: 10.1038/gim.2015.30.

## WORKFLOW

### 3-STEP PROCESS:

#### 1. Clinical Request

Exome sequencing can be focused on the patient alone (Disease Exome by CGC Genetics) or the patient and both biological parents (Whole Exome Sequencing TRIO).

Patient clinical information is crucial to deliver a well-founded diagnostic approach.


#### 2. Exome sequencing and variant confirmation

Exome sequencing uses Next Generation Sequencing (NGS) technology to perform sequencing analysis in a single test of WES TRIO or Disease Exome by CGC Genetics. Potential variants and/or disease-causing mutations are reanalyzed by Sanger sequencing, the gold standard of genetic diagnostics.

#### 3. Clinical analysis and integrated reports

Clinical reports are always based on individual patient information and analyzed by experienced senior geneticists.

Integrated reports are sent directly to the requesting physician through our secure online portal.



FOR MORE INFORMATION:  
[WWW.CGCGENETICS.COM](http://WWW.CGCGENETICS.COM)

**INTERNATIONAL**  
[CUSTOMERCARE@CGCGENETICS.COM](mailto:CUSTOMERCARE@CGCGENETICS.COM)

**PORTUGAL**  
[DCC@CGCGENETICS.COM](mailto:DCC@CGCGENETICS.COM) | +351 223 389 900

**SPAIN**  
[CLIENTES@CGCGENETICS.COM](mailto:CLIENTES@CGCGENETICS.COM) | +34 914 261 144

**USA**  
[INFO@CGCGENETICS.COM](mailto:INFO@CGCGENETICS.COM)

**CGC GENETICS**  
EXPERIENCE THE POWER OF CLINICAL GENETIC TESTING

Founded in 1992, CGC Genetics is one of the main European clinical genetics laboratories and leader in medical genetic tests in Portugal. CGC Genetics, with headquarters in Porto, reinforced its investment in Lisbon, USA (Newark) and Spain (Madrid) and, receives samples for genetic testing from all over the world, including hospitals, national and international, public and private, medical clinics, insurance companies and universities. Using vanguard technologies and strict quality policies, CGC Genetics has a clinical department with 5 Medical Genetics Specialists. In addition, more than 80 highly qualified Geneticists are divided into 5 different laboratory areas: Clinical Genomics, Molecular Diagnostics, Cytogenetics, Prenatal screening and Pathology, offering more than 4 000 genetic tests for prenatal diagnostic and screening, hematology, oncology, neurology, ophthalmology, cardiology, preventive medicine, common and rare diseases, pharmacogenetics/clinical trials. It has wide experience in Array CGH, NGS panels, Disease Exome and Whole Exome Sequencing, analyzed and interpreted with a high clinical integration. The large investment in R&D of new and unique tests, positioned CGC Genetics as an international reference center (with more than 3 800 entries in different directories of genetic tests), being the exclusive diagnostic test provider for some disorders. For more information, please contact us: [customercare@cgcgenetics.com](mailto:customercare@cgcgenetics.com)

Check the updated catalogue at [www.cgcgenetics.com](http://www.cgcgenetics.com)

Cofinanciado por:



FUNDO EUROPEU  
de Desenvolvimento Regional

